SCHEMBL23218759

SCHEMBL23218759

CCOC(=O)c1coc2cc(C)c(Cl)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.50
PTPN1 P18031 1/20 0.46
SIRT1 Q96EB6 1/20 0.44
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
BAZ2A Q9UIF9 1/20 0.43
TSHR P16473 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
CA12 O43570 3/20 0.39
CA9 Q16790 3/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28047037 0.84 MAOB (0.49) MAOBSIRT1CYP4F2CYP4A11BAZ2B
SCHEMBL26129410 0.83 MAOB (0.48) MAOBCYP4F2CYP4A11BAZ2BBAZ2A
SCHEMBL28047092 0.82 MAOB (0.47) MAOBSIRT1CYP4F2CYP4A11BAZ2B
SCHEMBL15898912 0.80 MAOB (0.57) MAOBSIRT1TSHRKDM4EKMT2A
SCHEMBL31661188 0.80 MAOB (0.50) MAOBTSHRKDM4EKMT2AALDH1A1
SCHEMBL4625705 0.76 CYP4F2 (0.53) CYP4F2CYP4A11BAZ2BBAZ2ATSHR
SCHEMBL31264497 0.76 MAOB (0.49) MAOBTSHRCA1CA2CA12
SCHEMBL26125713 0.76 MAOB (0.49) MAOBTSHRCA1CA2CA12
SCHEMBL31746125 0.75 MAOB (0.58) MAOBCYP4F2CYP4A11TSHRCA2
SCHEMBL28564405 0.75 NPC1 (0.58) MAOBSIRT1TSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885PTPN1 3533/4885SIRT1 4451/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885PTPN1 3369/4885SIRT1 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.